Our Leading Product : LIB-101

LIB-101 is a cytokine-based immunotherapy of the interleukin-12 (IL-12). As an effective immunomodulator, IL-12 helps regulate and rebalance an individual's immune environment. LIB-101 has a well-defined mechanism of action, engaging multiple pathways including innate immunity, adaptive immunity, and hematopoiesis.

Break The SOC(Standard of Care) Boundaries

Based on pharmacological mechanism, LIB-101 has the potential to be combined with current cancer SOC therapies—such as radiotherapy, chemotherapy, immune checkpoint inhibitors, and cell therapy—demonstrating a synergistic effect on treatment efficacy, while also showing a trend toward reducing the side effects of existing therapies. This supports the development of combination therapies that offer patients greater clinical benefit alongside improved quality of life.

LIB-101 Mechanism of Action

When combined with the anti-PD-1 checkpoint inhibitor, LIB-101 triggers interaction between T cells and dendritic cells, enhancing the IFN-γ/IL-12 positive feedback loop to boost anti-tumor efficacy.
Combining immunotherapy with LIB-101 can also strengthen the interaction between lymphoid and myeloid immunity.
Accelerating drug development through international strategic alliances

Compared to other industries, biopharmaceuticals are characterized by high risk, cross-disciplinary technology, long development timelines, and substantial capital requirements. Rather than pursuing traditional, closed, go-it-alone R&D, an innovative model that leverages extensive collaboration to diversify risk, improve capital efficiency, and reduce development barriers is better suited to the growth of the biopharmaceutical industry. Built on the foundation of strategic alliances, Libo Pharma extends its reach to domestic and international academic institutions, biotech companies, and global pharmaceutical companies, accelerating drug development through a collaborative alliance model.

Protecting intellectual property in early-stage collaborative development through a stealth mode approach

Libo Pharma respects the R&D achievements of every partner. The company continually seeks high-potential opportunities worldwide, committing resources through co-development, technology transfer, or varying degrees of investment and profit-sharing models. For every early-stage program, the company operates in stealth mode, disclosing only the minimum information necessary to protect the core commercial intellectual property of each development project.

Focus Areas

Hematologic Malignancies and Various Cancer Therapies
Novel cancer therapeutics to improve and extend the lives of patients, eg. immuno-oncology, antibody-drug conjugate, and etc.
Immune Dysregulation
To treat the dysfunction of the immune system with immunomodulator, eg. Diabetics, GVHD and etc.
Regenerative Medicine
Restore structure and function of damaged tissues, eg. wound healing, diabetic foot ulcer, chronic kidney disease and etc.